AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
November 09, 2018- New MappingHepC.com website provides HCV community an easily accessible source of chronic HCV epidemiology data
-
November 06, 2018
-
November 02, 2018- Reports Third-Quarter Diluted EPS of $1.81 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 51.8 Percent
-
November 01, 2018- The approval is based on the MURANO Phase 3 clinical trial, in which VENCLYXTO® plus rituximab reduced the risk of disease progression or death by 83 percent and overall survival was prolonged compared to bendamustine in combination with rituximab, a standard of care chemoimmunotherapy regimen¹
-
October 31, 2018- Randomized Phase 3 trial met primary endpoint, demonstrating patients treated with venetoclax plus obinutuzumab had superior progression-free survival (PFS) compared to patients treated with standard of care obinutuzumab plus chlorambucil
-
October 23, 2018- Upadacitinib monotherapy showed improvements in physical function, a measure that assesses patients' ability to perform daily activities and level of disability, versus methotrexate at week 14[1]
-
October 22, 2018- In U-ACHIEVE, upadacitinib (15/30/45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints, including endoscopic improvement, clinical remission (per Full Mayo Score) and clinical response, in patients with moderately to severely active ulcerative colitis[1]
-
October 18, 2018- Agreements Provide Non-Exclusive License to Fresenius Kabi for HUMIRA-Related Intellectual Property in the U.S. Effective September 30, 2023, and in Other Markets on Different Dates
-
October 18, 2018Collaboration leverages Morphic's unique platform for developing oral integrin drugs and AbbVie's global development and commercialization capabilities
-
October 17, 2018- If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatment
-
October 16, 2018- Eleven presentations of HUMIRA® (adalimumab) and pipeline data showcase breadth and depth of robust gastroenterology portfolio
-
October 08, 2018- Oral presentations include three of the five pivotal studies from AbbVie's SELECT Phase 3 program to support regulatory submission for investigational upadacitinib in patients with moderate to severe rheumatoid arthritis
-
September 21, 2018- If approved by the European Commission (EC), VENCLYXTO® plus rituximab would be the first chemotherapy-free combination regimen with a fixed duration of treatment for patients with chronic lymphocytic leukemia who have received at least one prior therapy.
-
September 17, 2018
-
September 13, 2018- Across all doses, a significantly greater proportion of patients who remained on upadacitinib showed continuous improvements in skin lesions and pruritus (itch) at week 32 compared to patients re-randomized to placebo[1]
-
September 13, 2018- Pooled analyses from ultIMMa-1 and ultIMMa-2 studies showed significantly more patients treated with risankizumab were symptom-free (psoriasis symptom scale [PSS] score of 0) compared to placebo and STELARA® (ustekinumab) after 16 weeks and at one year (52 weeks) compared to ustekinumab[1]
-
September 11, 2018- Minimal residual disease (MRD)-negativity is defined as having disease at a threshold of less than one chronic lymphocytic leukemia (CLL) cell per 10,000 lymphocytes in the blood or bone marrow[1]
-
September 07, 2018
-
September 04, 2018- Twenty-four presentations of HUMIRA® (adalimumab) and pipeline data showcase the breadth and depth of robust dermatology portfolio
-
August 27, 2018- Milestone represents ninth FDA approval for IMBRUVICA in less than five years since its initial approval
-
August 22, 2018- Study results (ELARIS UF-EXTEND) showed elagolix, in combination with add-back therapy, reduced heavy menstrual bleeding for up to 12 months
-
July 27, 2018- Reports Second-Quarter Diluted EPS of $1.26 on a GAAP Basis; Adjusted Diluted EPS of $2.00 Reflects Growth of 40.8 Percent
-
July 24, 2018- ORILISSA™ (elagolix) is the first FDA-approved oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade
-
June 26, 2018- Extension builds on collaboration established in 2014
-
June 25, 2018- The filing is based on data from the Phase 3 iNNOVATE study, which suggest that IMBRUVICA plus rituximab may improve outcomes across all lines of Waldenström's macroglobulinemia (WM) treatment, including patients with prior lines of therapy and various genetic factors, versus rituximab alone
-
June 25, 2018- Collaboration will focus on switchable CAR-T therapies aimed primarily at solid tumors
-
June 15, 2018- 83 percent (n=100) of 121 patients who achieved undetectable minimal residual disease (uMRD) at the end of combination therapy with VenR (n=194), maintained uMRD and were progression-free at 13.8 months of follow-up[1]
-
June 14, 2018
-
June 12, 2018- Upadacitinib showed improvements in physical function, a measure that assesses patients' ability to perform daily activities and level of disability(1,2,3)
-
June 08, 2018-- In the MURANO Phase 3 clinical trial, the VENCLEXTA® (venetoclax tablets) plus rituximab combination showed a significant improvement in progression-free survival (PFS) for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients, reducing the risk of disease progression or death by 81 percent when compared to a standard of care chemoimmunotherapy regimen, bendamustine plus rituximab (1)
-
June 05, 2018- In SELECT-EARLY, upadacitinib monotherapy (15/30 mg, once-daily) met both primary endpoints, with 52/56 percent of methotrexate-naïve patients achieving ACR50 at week 12 and 48/50 percent achieving clinical remission at week 24, respectively(1)
-
June 04, 2018
-
June 03, 2018- Approximately nine out of 10 of the first CLL patients treated achieved responses with no detectable minimal residual disease (MRD) based on a specific test to detect cancer cells in the bone marrow
-
June 01, 2018- Study data suggest IMBRUVICA plus rituximab could provide a new option across all lines of WM treatment, regardless of prognostic or genotypic factors
-
May 31, 2018- Results from a sub-analysis of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) who achieved undetectable minimal residual disease in the Phase 3 MURANO investigational study of venetoclax in combination with rituximab will be featured in an oral presentation
-
May 30, 2018
-
May 24, 2018Phase 3 iLLUMINATE trial met primary endpoint of progression-free survival (PFS) in patients with previously untreated CLL and Small Lymphocytic Lymphoma (SLL) compared to chlorambucil plus obinutuzumab as assessed by an Independent Review Committee (IRC)
-
May 16, 2018- More than 30 abstracts accepted across hematologic malignancies, solid tumors and other oncology-related diseases
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
